The objective of this post marketing surveillance is according to § 67 Abs. 6 AMG the documentation of data concerning clinical efficiency and safety of Herceptin (Trastuzumab) in HER2 positive metastatic adenocarcinoma of the stomach or GEJ in routine clinical practice.

The purpose of this investigation is to document the application of Herceptin as a part of routine treatment in Germany. The implementation of this post marketing surveillance does not influence the physician regarding therapy, diagnostics and frequency of medical examination during and after the treatment.